About Fortrea Holdings Inc.
https://www.fortrea.comFortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
CEO
Anshul Thakral
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 178
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Citigroup
Buy
Baird
Outperform
Barclays
Equal Weight
William Blair
Market Perform
Evercore ISI Group
In Line
Mizuho
Neutral
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:16.14M
Value:$270.62M
BLACKROCK, INC.
Shares:14.19M
Value:$237.96M
VANGUARD GROUP INC
Shares:8.07M
Value:$135.38M
Summary
Showing Top 3 of 361
About Fortrea Holdings Inc.
https://www.fortrea.comFortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $701.3M ▼ | $119M ▼ | $-15.9M ▲ | -2.27% ▲ | $-0.17 ▲ | $13.5M ▲ |
| Q2-2025 | $710.3M ▲ | $124.8M ▼ | $-374.9M ▲ | -52.78% ▲ | $-4.14 ▲ | $-327.9M ▲ |
| Q1-2025 | $651.3M ▼ | $636.6M ▲ | $-562.9M ▼ | -86.43% ▼ | $-6.3 ▼ | $-506.2M ▼ |
| Q4-2024 | $697M ▲ | $196.5M ▲ | $-61.2M ▼ | -8.78% ▼ | $-0.68 ▼ | $-32.2M ▼ |
| Q3-2024 | $674.9M | $166.3M | $-27.9M | -4.13% | $-0.31 | $7.8M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $131.3M ▲ | $2.74B ▼ | $2.16B ▼ | $580.8M ▼ |
| Q2-2025 | $81.2M ▼ | $2.84B ▼ | $2.25B ▼ | $589.2M ▼ |
| Q1-2025 | $101.6M ▼ | $3.12B ▼ | $2.26B ▲ | $858.8M ▼ |
| Q4-2024 | $118.5M ▲ | $3.58B ▼ | $2.22B ▲ | $1.36B ▼ |
| Q3-2024 | $105.3M | $3.66B | $2.15B | $1.51B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-15.9M ▲ | $86.8M ▲ | $13.3M ▲ | $-50M ▼ | $50.1M ▲ | $79.5M ▲ |
| Q2-2025 | $-374.9M ▲ | $21.8M ▲ | $-7.5M ▼ | $-39M ▼ | $-20.4M ▼ | $14.3M ▲ |
| Q1-2025 | $-562.9M ▼ | $-124.2M ▼ | $16.1M ▲ | $88.4M ▲ | $-16.9M ▼ | $-127.1M ▼ |
| Q4-2024 | $-73.9M ▼ | $17.1M ▲ | $3.5M ▲ | $-1.1M ▲ | $13.2M ▲ | $20.3M ▲ |
| Q3-2024 | $-27.9M | $-2.4M | $-8.1M | $-14M | $-20.9M | $-10.6M |
Revenue by Products
| Product | Q4-2023 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Clinical Services Segment | $1.40Bn ▲ | $650.00M ▼ | $710.00M ▲ | $700.00M ▼ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Europe | $400.00M ▲ | $210.00M ▼ | $220.00M ▲ | $200.00M ▼ |
 North America | $640.00M ▲ | $330.00M ▼ | $340.00M ▲ | $310.00M ▼ |
 Other Geographical Areas | $320.00M ▲ | $160.00M ▼ | $150.00M ▼ | $140.00M ▼ |
CEO
Anshul Thakral
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 178
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Citigroup
Buy
Baird
Outperform
Barclays
Equal Weight
William Blair
Market Perform
Evercore ISI Group
In Line
Mizuho
Neutral
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:16.14M
Value:$270.62M
BLACKROCK, INC.
Shares:14.19M
Value:$237.96M
VANGUARD GROUP INC
Shares:8.07M
Value:$135.38M
Summary
Showing Top 3 of 361